About the Event
Skin conditions represent the largest single category of human diseases. Currently patients with eczema, rosacea, alopecia , and vitiligo spend upwards of $13B a year for systemic treatments with varying degrees of success and significant side effects.
CAGE Bio has developed an Ionic Liquid (IL) platform that allows medication to be applied topically to the area of need with exceptional efficacy. This enables the company to engineer diverse Ionic Liquids targeted for multiple therapeutic areas.
CAGE Bio has a robust pipeline of Ionic Liquid formulations and have begun to enroll patients in Phase 2 trials of the rosacea program after a very successful Phase 1.
Join our webinar to hear from CAGE Bio CEO, Nitin Joshi as he discusses the opportunity this breakthrough technology presents.